Siolta Therapeutics Announces First Newborn Dosed in Their Phase 2 ADORED Study Evaluating a Potential First-In-Class Live Biotherapeutic Product for the Prevention of Atopic Diseases  https://t.co/iNo7lVcGvw  https://t.co/t0jxMuMBmZ